drug

OXCARBAZEPINE

Marketedupdated 3mo ago

by Aucta Pharmaceuticals Inc

Approved

community read0 votes

🐶 often sniffed alongside

top 5

Small molecule drug with a maximum clinical stage of Approval (across all indications), with an approval for epilepsy and seizure and 7 investigational indications.

all catalysts(64)

approval · 64

TRILEPTAL (OXCARBAZEPINE) — FDA approval

TRILEPTAL (OXCARBAZEPINE) — FDA approval

TRILEPTAL (OXCARBAZEPINE) — FDA approval

TRILEPTAL (OXCARBAZEPINE) — FDA approval

TRILEPTAL (OXCARBAZEPINE) — FDA approval

TRILEPTAL (OXCARBAZEPINE) — FDA approval

TRILEPTAL (OXCARBAZEPINE) — FDA approval

TRILEPTAL (OXCARBAZEPINE) — FDA approval

TRILEPTAL (OXCARBAZEPINE) — FDA approval

TRILEPTAL (OXCARBAZEPINE) — FDA approval

TRILEPTAL (OXCARBAZEPINE) — FDA approval

TRILEPTAL (OXCARBAZEPINE) — FDA approval

TRILEPTAL (OXCARBAZEPINE) — FDA approval

TRILEPTAL (OXCARBAZEPINE) — FDA approval

TRILEPTAL (OXCARBAZEPINE) — FDA approval

TRILEPTAL (OXCARBAZEPINE) — FDA approval

TRILEPTAL (OXCARBAZEPINE) — FDA approval

TRILEPTAL (OXCARBAZEPINE) — FDA approval

TRILEPTAL (OXCARBAZEPINE) — FDA approval

TRILEPTAL (OXCARBAZEPINE) — FDA approval

TRILEPTAL (OXCARBAZEPINE) — FDA approval

TRILEPTAL (OXCARBAZEPINE) — FDA approval

TRILEPTAL (OXCARBAZEPINE) — FDA approval

TRILEPTAL (OXCARBAZEPINE) — FDA approval

TRILEPTAL (OXCARBAZEPINE) — FDA approval

TRILEPTAL (OXCARBAZEPINE) — FDA approval

TRILEPTAL (OXCARBAZEPINE) — FDA approval

TRILEPTAL (OXCARBAZEPINE) — FDA approval

TRILEPTAL (OXCARBAZEPINE) — FDA approval

TRILEPTAL (OXCARBAZEPINE) — FDA approval

TRILEPTAL (OXCARBAZEPINE) — FDA approval

TRILEPTAL (OXCARBAZEPINE) — FDA approval

TRILEPTAL (OXCARBAZEPINE) — FDA approval

TRILEPTAL (OXCARBAZEPINE) — FDA approval

TRILEPTAL (OXCARBAZEPINE) — FDA approval

TRILEPTAL (OXCARBAZEPINE) — FDA approval

TRILEPTAL (OXCARBAZEPINE) — FDA approval

TRILEPTAL (OXCARBAZEPINE) — FDA approval

TRILEPTAL (OXCARBAZEPINE) — FDA approval

TRILEPTAL (OXCARBAZEPINE) — FDA approval

TRILEPTAL (OXCARBAZEPINE) — FDA approval

TRILEPTAL (OXCARBAZEPINE) — FDA approval

TRILEPTAL (OXCARBAZEPINE) — FDA approval

TRILEPTAL (OXCARBAZEPINE) — FDA approval

TRILEPTAL (OXCARBAZEPINE) — FDA approval

TRILEPTAL (OXCARBAZEPINE) — FDA approval

TRILEPTAL (OXCARBAZEPINE) — FDA approval

TRILEPTAL (OXCARBAZEPINE) — FDA approval

TRILEPTAL (OXCARBAZEPINE) — FDA approval

TRILEPTAL (OXCARBAZEPINE) — FDA approval

TRILEPTAL (OXCARBAZEPINE) — FDA approval

TRILEPTAL (OXCARBAZEPINE) — FDA approval

TRILEPTAL (OXCARBAZEPINE) — FDA approval

TRILEPTAL (OXCARBAZEPINE) — FDA approval

TRILEPTAL (OXCARBAZEPINE) — FDA approval

TRILEPTAL (OXCARBAZEPINE) — FDA approval

TRILEPTAL (OXCARBAZEPINE) — FDA approval

TRILEPTAL (OXCARBAZEPINE) — FDA approval

TRILEPTAL (OXCARBAZEPINE) — FDA approval

TRILEPTAL (OXCARBAZEPINE) — FDA approval

TRILEPTAL (OXCARBAZEPINE) — FDA approval

TRILEPTAL (OXCARBAZEPINE) — FDA approval

OXCARBAZEPINE — FDA approval

TRILEPTAL (OXCARBAZEPINE) — FDA approval

OXCARBAZEPINE

→

view all 64 catalysts →

Trials studying OXCARBAZEPINE

phase1Steady-state Pharmacokinetics of BIA 2-093 and Oxcarbazepine in Healthy Volunteerscompletedn=12
phase1Oxcarbazepine 600 mg Tablets Under Fasting Conditionscompletedn=60
phase1Oxcarbazepine 600 mg Tablets Under Non-Fasting Conditionscompletedn=120
—Longitudinal Comparative Effectiveness of Bipolar Disorder Therapiesterminatedn=1,037,352
phase4The Efficacy and Safety of Oral Oxcarbazepine 300-1200 mg/Day as Adjuvant Therapy in the Treatment of Bipolar Disorder I or II This Study is Not Being Conducted in the United States.completedn=55

Patent cliff

source: FDA Orange Book

first barrier falls

Apr 13, 2027

241 days

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (33)

Apr 13, 2027method-of-use (U-2501)US 10220042241d
Apr 13, 2027method-of-use (U-2501)US 10220042241d
Apr 13, 2027method-of-use (U-2501)US 10220042241d
Apr 13, 2027formulationUS 11166960241d
Apr 13, 2027formulationUS 11166960241d
Apr 13, 2027formulationUS 11166960241d
Apr 13, 2027formulationUS 11896599241d
Apr 13, 2027formulationUS 11896599241d
Apr 13, 2027formulationUS 11896599241d
Apr 13, 2027formulationUS 7722898241d
Apr 13, 2027formulationUS 7722898241d
Apr 13, 2027formulationUS 7722898241d
Apr 13, 2027method-of-use (U-2041)US 7910131241d
Apr 13, 2027method-of-use (U-2041)US 7910131241d
Apr 13, 2027method-of-use (U-2041)US 7910131241d
Apr 13, 2027formulationUS 8617600241d
Apr 13, 2027formulationUS 8617600241d
Apr 13, 2027formulationUS 8617600241d
Apr 13, 2027formulationUS 8821930241d
Apr 13, 2027formulationUS 8821930241d
Apr 13, 2027formulationUS 8821930241d
Apr 13, 2027method-of-use (U-2041)US 9119791241d
Apr 13, 2027method-of-use (U-2041)US 9119791241d
Apr 13, 2027method-of-use (U-2041)US 9119791241d
Apr 13, 2027formulationUS 9351975241d
Apr 13, 2027formulationUS 9351975241d
Apr 13, 2027formulationUS 9351975241d
Apr 13, 2027formulationUS 9370525241d
Apr 13, 2027formulationUS 9370525241d
Apr 13, 2027formulationUS 9370525241d
Apr 13, 2027formulationUS 9855278241d
Apr 13, 2027formulationUS 9855278241d
Apr 13, 2027formulationUS 9855278241d

News(0)

no news has mentioned this drug yet

brand

OXCARBAZEPINE

generic

OXCARBAZEPINE

MOA

12.1 Mechanism of Action The pharmacological activity of TRILEPTAL is primarily exerted through the 10-monohydroxy metabolite (MHD) of oxcarbazepine [ see Clinical Pharmacology (12.3) ]. The precise mechanism by which oxcarbazepine and MHD exert their anti-seizure effect is unknown; however, in vitro electrophysiological studies indicate that they produce blockade of voltage-sensitive sodium channels, resulting in stabilization of hyperexcited neural membranes, inhibition of repetitive neuronal firing, and diminution of propagation of synaptic impulses. These actions are thought to be important in the prevention of seizure spread in the intact brain. In addition, increased potassium conductance and modulation of high-voltage activated calcium channels may contribute to the anticonvulsant effects of the drug. No significant interactions of oxcarbazepine or MHD with brain neurotransmitter or modulator receptor sites have been demonstrated.

indication

Partial Seizure

phase

marketed

Data sources

openFDA · ClinicalTrials.gov

last refreshed 31m ago

Found something off?

comments(0)

5-min edit window · permanent after that

no comments yet — first sniff?

OXCARBAZEPINE

🐶 often sniffed alongside

all catalysts(64)

Trials studying OXCARBAZEPINE

Patent cliff

patents (33)

News(0)

Report a data issue

comments(0)

OXCARBAZEPINE

🐶 often sniffed alongside

all catalysts(64)

Trials studying OXCARBAZEPINE

Patent cliff

patents (33)

News(0)

Report a data issue

comments(0)